BR111 for advanced cancers
Part of Cancer clinical trials.
This is an early-phase study testing a new drug called BR111 for people with advanced solid tumors or B-cell lymphoma who have run out of effective options. The trial helps find the right dose and checks if the drug is safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced cancer (solid tumor or lymphoma) that has not responded to or you cannot tolerate standard treatments.
- You are 18 years or older and willing to provide a tumor sample for testing.
- Your daily life is not severely limited (ECOG score 0 or 1), and doctors expect you to live at least 3 more months.
- You have not previously received treatment targeting ROR1 or the drug eribulin.
- Your cancer has not spread to your brain causing symptoms, or if it has, it is stable and untreated for at least 4 weeks.
- You do not have serious lung disease, uncontrolled heart problems, or a history of certain skin conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called BL-B16D1 for people with advanced breast cancer or other solid tumors that have not responded to standard treatments. The goal is to see if the drug is safe and how well it works.
This study tests a new drug, BL-B16D1, for people with advanced head and neck cancer or other solid tumors that have not been helped by standard treatments. The goal is to see if the drug is safe and effective.
This study tests a new experimental drug called BR113, given as an injection, for people with advanced solid tumor cancers that have stopped responding to standard treatments. The goal is to see if the drug is safe and effective in shrinking or controlling the cancer.
This study tests a new drug called HX111 for people with advanced solid tumors or certain lymphomas that have not responded to standard treatments. The goal is to see if the drug is safe and effective against these cancers.
This Phase 1 trial tests INBRX-109, a cancer-targeting drug, in people whose solid cancers are locally advanced or spread to other parts of the body. Because it’s Phase 1, the main goal is to see whether it’s safe and how well it can work for different tumor types that meet specific requirements.
This study tests a new drug called BI 3822971 for people with advanced cancer that has not responded to standard treatments. The goal is to find the best dose that is safe and well-tolerated.
Hear when a new Advanced Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.